A report from Elsevier shows that research funders are facing significant gaps between their stated priorities and the implementation of such priorities, particularly in aligning funding with societal ...

Elsevier, publisher of science journals and clinical decision-support tools, is rolling out an AI-powered research tool it says is built to transform how researchers work. LeapSpace is an AI-assisted ...

Elsevier Health has launched an generative AI-driven version of its flagship clinical decision support tool, ClinicalKey, in partnership with AI company OpenEvidence. The latest add-on module offers ...

The National Science Foundation’s Directorate for Technology, Innovation and Partnerships, or TIP, has introduced a public data platform designed to provide insights into how NSF allocates funding ...

The University of California System has canceled its multimillion-dollar subscription contract with Elsevier, an academic publisher. Other institutions have canceled their “big deal” journal ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. In 1995, Forbes, the business magazine, made a prediction: Elsevier, the largest publisher of scientific ...

After a year of talks, Dutch publishing giant Elsevier has struck a deal with a group of Norwegian universities that will allow academics to publish the vast majority of their work under open-access ...

Scientific publishing giant Elsevier put out a total of six publications between 2000 and 2005 that were sponsored by unnamed pharmaceutical companies and looked like peer reviewed medical journals, ...

Elsevier this week announced its acquisition of Pittsburgh-based Via Oncology, a former subsidiary of UPMC that develops clinical decision support tools for cancer care management. Via Oncology's ...

A scholarly journal run by the Dutch publishing giant Elsevier has come under scrutiny for rejecting a paper submitted for publication because, among other reasons, it didn’t cite enough of the ...

Academic publishing is a very good game indeed if you can manage to get into it. As the publisher the work is created at the expense of others, for free to you. There are no advances, no royalties, to ...